Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3989315 | 1.00 | CTSS (0.60) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL9963893 | 0.89 | CTSS (0.60) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL740864 | 0.88 | CTSS (0.60) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL476153 | 0.88 | JAK3 (0.48) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL6345086 | 0.88 | JAK3 (0.51) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL13977456 | 0.88 | CTSS (0.60) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL7033261 | 0.88 | PPARG (0.52) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL476152 | 0.88 | JAK3 (0.48) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL740863 | 0.88 | CTSS (0.60) | CTSSCTSKJAK3BTKCTSL | |
| SCHEMBL268923 | 0.88 | JAK3 (0.51) | CTSSCTSKJAK3BTKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051283-A1 | THERAPEUTIC COMPOUNDS AND METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-02-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514430-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-6974869-B2 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | DELUCCA GEORGE V | 2005-11-24 | — | — | US | disclosed |
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144277-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | CTSS 2447/4885CTSK 2578/4885JAK3 504/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CTSS 210/4885CTSK 174/4885JAK3 4766/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CTSS 199/4885CTSK 307/4885JAK3 4609/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CTSS 210/4885CTSK 174/4885JAK3 4766/4885 |
| US-20050261311-A1 | Piperizinones as modulators of chemokine receptor activity | CCR3, CCR1, CCR5 | CTSS 2327/4885CTSK 2434/4885JAK3 468/4885 |
| US-20250051283-A1 | THERAPEUTIC COMPOUNDS AND METHODS | EIF2AK2, SARS1, REN | CTSS 1617/4885CTSK 3060/4885JAK3 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.